{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:29:12Z","timestamp":1792099752419,"version":"4.4.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1097\/md.0000000000011322","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T22:48:35Z","timestamp":1530053315000},"page":"e11322","source":"Crossref","is-referenced-by-count":17,"title":["Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan"],"prefix":"10.1097","volume":"97","author":[{"given":"Yu-Fen","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Feng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Fung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Sung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-84-20210226","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression","volume":"16","author":"Shet","year":"2002","journal-title":"Leukemia"},{"key":"R2-84-20210226","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-84-20210226","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R4-84-20210226","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"R5-84-20210226","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"R6-84-20210226","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.critrevonc.2015.08.025","article-title":"To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients","volume":"97","author":"Hall","year":"2016","journal-title":"Crit Reviews Oncol Hematol"},{"key":"R7-84-20210226","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"key":"R8-84-20210226","first-page":"120","article-title":"Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients","volume":"36","author":"Chen","year":"2014","journal-title":"I J C Pharm"},{"key":"R9-84-20210226","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"key":"R10-84-20210226","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R11-84-20210226","first-page":"59","article-title":"New medication adherence scale versus pharmacy fill rates in seniors with hypertension","volume":"15","author":"Krousel-Wood","year":"2009","journal-title":"Am J Manag Care"},{"key":"R12-84-20210226","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jclinepi.2010.09.002","article-title":"Improving the measurement of self-reported medication nonadherence: final response","volume":"64","author":"Morisky","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R13-84-20210226","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"R14-84-20210226","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"R15-84-20210226","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12032-017-0958-6","article-title":"Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors","volume":"34","author":"Rychter","year":"2017","journal-title":"Med Oncol"},{"key":"R16-84-20210226","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"R17-84-20210226","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.leukres.2008.04.018","article-title":"Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase","volume":"33","author":"Kiguchi","year":"2009","journal-title":"Leuk Res"},{"key":"R18-84-20210226","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1037\/0278-6133.23.2.207","article-title":"Social support and patient adherence to medical treatment: a meta-analysis","volume":"23","author":"DiMatteo","year":"2004","journal-title":"Health Psychol"},{"key":"R19-84-20210226","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"R20-84-20210226","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"R21-84-20210226","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/PPA.S70712","article-title":"Chronic myeloid leukemia patients\u2019 adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians","volume":"8","author":"Kekale","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"R22-84-20210226","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"key":"R23-84-20210226","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/PPA.S92125","article-title":"Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment","volume":"9","author":"Kekale","year":"2015","journal-title":"Patient Prefer Adherence"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000011322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:15:27Z","timestamp":1620962127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201806290-00084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":23,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000011322","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}